PCSK9 Inhibitors Provide an Added Tool to Cardiac Care Armamentarium

With statins being a common treatment option to help patients reduce their cholesterol levels, the still relatively newly approved PCSK9 inhibitors have proven a valuable tool. However, they are not enough to help eliminate concerns about cardiac care and cholesterol.

While the newer agents can provide a powerful boost in the fight against high cholesterol, Sheldon Koenig from Sanofi, said they are not meant to replace statins in most patients. Jay Edelberg, MD, PhD, also from Sanofi, said statins remain the "standard of care," and that the PCSK9 inhibitors are intended to be used "on top of," statin treatment for the best possible results. The latest data on Praluent was discussed during the annual American Heart Association's Scientific Sessions in New Orleans, LA.